Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HIV-1 envelope glycoprotein gp120–gp41 interface is the interaction region between the surface subunit gp120 and the transmembrane subunit gp41 of the HIV-1 envelope spike (Env) complex. This trimeric structure is crucial for HIV-1 cell entry, mediating viral attachment via gp120 binding to the host CD4 receptor and chemokine co-receptors, followed by gp41-driven viral–cell membrane fusion. The interface is a dynamic, structurally complex region and a critical target for broadly neutralizing antibodies and fusion inhibitors, but its high degree of conformational plasticity and glycan shielding make it challenging for vaccine and drug design. Therapies targeting this site aim to block the entry process and prevent HIV-1 infection, but viral escape remains a major challenge.
Inhibitor peptides (e.g., enfuvirtide) block refolding of gp41, preventing membrane fusion. Monoclonal antibodies bind to quaternary epitopes at the gp120–gp41 interface, blocking conformational changes required for fusion or neutralizing the virus. Some small molecules disrupt the conformational transitions needed for fusion (rare, mostly experimental)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIV-1 envelope glycoprotein gp120–gp41 interface.